RECORD // Company

Pluri Inc.

Formerly: PLURISTEM THERAPEUTICS INC; PLURISTEM LIFE SYSTEMS INC; AI SOFTWARE INC

Built 2026-11-22T01:07:02Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
  • Pluri Inc. · the SEC registrant record of this company

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-12 · accession 0001213900-26-118901

ItemValuePeriodFormFiledAccessionReport
Revenue$759,0003 months ended 2026-09-3010-Q2026-11-120001213900-26-1189012026-11-22 01:07 UTCReport an error
Net income (loss)$-10,390,0003 months ended 2026-09-3010-Q2026-11-120001213900-26-1189012026-11-22 01:07 UTCReport an error
Interest expense$226,0003 months ended 2026-09-3010-Q2026-11-120001213900-26-1189012026-11-22 01:07 UTCReport an error
Cash and cash equivalents$3,460,000at 2026-09-3010-Q2026-11-120001213900-26-1189012026-11-22 01:07 UTCReport an error
Contract liabilities (total) (from an earlier report)$148,000at 2026-06-3010-K2026-09-100001213900-26-0988622026-11-22 01:07 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001158780
Ticker
PLUR
EIN
980351734
CUSIP
72942G203
Record ID
sx:sec:0001158780

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

39 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 01:07 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-16SEC EDGAR company profile2026-11-22 01:07 UTCReport an error
State of incorporationNV2026-11-16SEC EDGAR company profile2026-11-22 01:07 UTCReport an error
Fiscal year end (MMDD)06302026-11-16SEC EDGAR company profile2026-11-22 01:07 UTCReport an error
Business addressMATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA2026-11-16SEC EDGAR company profile2026-11-22 01:07 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 01:07 UTCReport an error
Revenue (fiscal year ended 2026-06-30)$1,016,0002026-06-3010-K, XBRL Revenues2026-11-22 01:07 UTCReport an error
Net income (loss) (fiscal year ended 2026-06-30)$-23,821,0002026-06-3010-K, XBRL NetIncomeLoss2026-11-22 01:07 UTCReport an error
Total assets (at 2026-06-30)$24,878,0002026-06-3010-K, XBRL Assets2026-11-22 01:07 UTCReport an error
Stockholders' equity (at 2026-06-30)$-23,036,0002026-06-3010-K, XBRL StockholdersEquity2026-11-22 01:07 UTCReport an error
Cash and cash equivalents (at 2026-06-30)$3,529,0002026-06-3010-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 01:07 UTCReport an error
Operating cash flow (fiscal year ended 2026-06-30)$-19,588,0002026-06-3010-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 01:07 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2026-06-30)$633,0002026-06-3010-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 01:07 UTCReport an error
Operating lease liabilities (at 2026-06-30)$7,483,0002026-06-3010-K, XBRL OperatingLeaseLiability2026-11-22 01:07 UTCReport an error
Form D total offering amount (D filed 2026-09-04)$3,677,7512026-09-04D2026-11-22 01:07 UTCReport an error
Form D total amount sold (D filed 2026-09-04)$3,677,7512026-09-04D2026-11-22 01:07 UTCReport an error
Form D industry groupBiotechnology2026-09-04D2026-11-22 01:07 UTCReport an error
Form D revenue rangeDecline to Disclose2026-09-04D2026-11-22 01:07 UTCReport an error
Form D date of first sale2026-08-282026-09-04D2026-11-22 01:07 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive (filed 2026-10-30)Agreement. ZEO Partnership Agreement On October 26, 2026, Pluri Inc. (“Pluri” or the “Company”) entered into a Partnership Agreement (the “Agreement”) with ZEO ScientifiX, Inc. (“ZEO”) pursuant to which, at the closing of the transactions contemplated under the Agreement the Company shall grant ZEO an exclusive license solely to manufacture and commercialize its regenerative medicine product portfolio (except where such products are intended for aesthetics, skin care, cosmetic, or veterinary applications, in which case ZEO may only commercialize such products) in the United States (the “License”), which may also be expanded to Latin America under the terms of the Agreement. Pursuant to the…2026-10-30SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity (filed 2026-10-30)Securities. The information set forth under the subheadings “ZEO Partnership Agreement” and “Securities Purchase Agreements” in2026-10-30SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 1.01, of this Current Report on Form 8-K are incorporated into this Item 3.02 by reference (filed 2026-10-30)The ZEO Transaction Securities described under the subheading “ZEO Partnership Agreement” in Item 1.01 above were offered and agreed to be sold in reliance upon exemptions from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. The offer and sale of the Securities did not involve any general solicitation or general advertising. The Securities have not been registered under the Securities Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration…2026-10-30SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-30)As previously disclosed, the Company, together with its subsidiaries, Pluri Biotech Ltd., incorporated under the laws of Israel, and Pluristem GmbH, incorporated under the laws of Germany (the “Subsidiaries”), entered into a finance agreement with the European Investment Bank (“EIB”) providing for up to €50 million in funding, of which only the first tranche of €20 million was disbursed in June 2021, and such amount bears interest at 4% per annum, and was scheduled to become repayable on June 1, 2026 (as amended by the Consent and Amendment Letter No, 1, dated as of February 10, 2025, the “Loan”). The Company also previously disclosed that on April 21, 2026, the Company received notice from…2026-10-30SEC EDGAR 8-K 0001213900-26-114079 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-20)As previously disclosed, on June 14, 2026, Pluri Inc. (the “Company”) entered into an advance subscription agreement with Chutzpah Holdings LP (the “Purchaser”), a limited partnership beneficially owned by Mr. Alexandre Weinstein, a non-U.S. investor, the Company’s largest existing shareholder and the chairman of the board of directors of the Company (the “Board”), pursuant to which the Purchaser paid the Company $1,250,000 on June 16, 2026 as an advance payment to be credited against the purchase price payable by the Purchaser for securities to be purchased in a future financing, subject to the approval of the Board. On October 19, 2026, following approval by the Board, the Company and the…2026-10-20SEC EDGAR 8-K 0001213900-26-111015 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-20)Pursuant to the Purchase Agreement described in2026-10-20SEC EDGAR 8-K 0001213900-26-111015 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 1.01, above, which description is incorporated into this Item 3.02 by reference, the Securities were issued in reliance upon the exemption (filed 2026-10-20)from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) and Rule 903 of Regulation S promulgated thereunder. The sale of the Securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Securities have not been registered under the Securities Act or any state securities laws and such securities may not be offered or sold in the United States absent registration, or an exemption from registration, under the Securities Act and any applicable state securities law. 12026-10-20SEC EDGAR 8-K 0001213900-26-111015 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-08-28)On August 26, 2026, Pluri Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Registered Direct Offering”) registered under the Securities Act of 1933, as amended (the “Securities Act”), an aggregate of (i) 1,200,000 (the “Shares”) of the Company’s common shares (“Common Shares”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,028,940 Common Shares (such shares issuable upon exercise of the Pre-Funded Warrants, the “Pre-Funded Warrant Shares”, and together with the Shares and…2026-08-28SEC EDGAR 8-K 0001213900-26-094638 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-08-28)Pursuant to the Concurrent Private Placement described in Item 1.01 above, which description is incorporated into this Item 3.02 by reference, the Common Warrants (including the Common Stock issuable upon exercise of the Common Warrants) (collectively, the “Private Securities”) were issued in reliance upon the exemption from registration pursuant to Section 4(a)(2) under the Securities Act and Regulation D under the Securities Act, and corresponding provisions of state securities or “blue sky” laws. The sale of the Private Securities did not involve a public offering and was made without general solicitation or general advertising. Accordingly, the Private Securities have not been…2026-08-28SEC EDGAR 8-K 0001213900-26-094638 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-08-17)On August 12, 2026, Ever After Foods Ltd. (“EAF”), an indirect majority-owned subsidiary of Pluri Inc. (the “Company”), entered into a share purchase agreement (the “Share Purchase Agreement”) with Fishway BV (“Fishway”) and the holders of certain securities of Fishway as specified in the Share Purchase Agreement (the “Sellers”). Pursuant to the Share Purchase Agreement, and subject to the satisfaction or waiver of customary closing conditions, EAF agreed to acquire all of the outstanding share capital of Fishway in exchange for the issuance of EAF’s ordinary shares to the Sellers (the “Transaction”). The Transaction is intended to support EAF’s European strategy through Fishway’s Belgian…2026-08-17SEC EDGAR 8-K 0001213900-26-090738 (text as filed, excerpt)2026-11-22 01:07 UTCReport an error
Largest institutional holder #1 (13F as filed): RENAISSANCE TECHNOLOGIES LLC$38,2972026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #2 (13F as filed): EverSource Wealth Advisors, LLC$4,1802026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #3 (13F as filed): UBS Group AG$4,0092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #4 (13F as filed): SIMA Wealth Partners, LLC$7322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #5 (13F as filed): CITIGROUP INC$3932026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #6 (13F as filed): WELLS FARGO & COMPANY/MN$3862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #7 (13F as filed): JPMORGAN CHASE & CO$2692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #8 (13F as filed): SBI Securities Co., Ltd.$2032026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #9 (13F as filed): TD Waterhouse Canada Inc.$1982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error
Largest institutional holder #10 (13F as filed): Activest Wealth Management$1772026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:07 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.